Formulation and Evaluation of Nasal drug delivery of certain drugs / (رقم التسجيلة. 179234)
[ عرض عادي ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 06412namaa22004451i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | EG-GICUC |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20260422103413.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 260406s2025 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.4 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 615.4 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.08.08.M.Sc.2025.As.F |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Asmaa Mohamed Abdel-Haleem Ramadan, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Formulation and Evaluation of Nasal drug delivery of certain drugs / |
| Statement of responsibility, etc. | by Asmaa Mohamed Abdel-Haleem Ramadan ; Supervision Prof. Dr. Mohamed Ahmed El-Nabarawi, Prof. Dr. Mahmoud Hassan Teaima, Dr. Samar Fathy Elhabal. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | صياغة وتقييم بعض أنظمة العلاج عن طريق الانف |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2025. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 111 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (M.Sc)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 87 -111. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | Allergic rhinitis has shown a rising prevalence throughout the <br/>years, necessitating the implementation of more effective and safe <br/>treatment strategies. Levocetirizine (LVC) is indicated for the treatment <br/>of allergic conditions such as Allergic Rhinitis and Allergic <br/>Conjunctivitis, atopic and contact dermatitis, eczema, and urticarial. In <br/>the present study, a transethosomal thermosensitive in situ gel was <br/>developed as an intranasal delivery platform for nasal mucosa to prove <br/>to be effective in treating AR animal models for the first time. Thin <br/>film hydration was used to create LVC-loaded transethosomes (LVC-<br/>TEs) and assess their zeta potential, particle size, polydispersity index, <br/>and entrapment efficiency (EE %). Additionally, TEM and FTIR <br/>investigations were performed on the optimized LVC-TE formulation <br/>(TE1). The optimized formula integrates into a thermosensitive in-situ <br/>gel based on poloxamer 407 and 188, and hydroxypropyl <br/>methylcellulose as a mucoadhesive polymer (TE1-ISG). The evaluation <br/>of TE1-ISG involved assessing various parameters, and ex-vivo <br/>permeation. TE1 displayed smooth spherical nanoparticles with the <br/>highest EE% (92.58±1.21), lowest particle size (130.64±2.10 nm), <br/>polydispersity index (0.46±0.04), and zeta potential (19.52±0.52 mV). <br/>The release profile of TE1 displayed an initial burst followed by <br/>sustained release within 24 hr. AR was experimentally induced in 24 <br/>rats through ovalbumin sensitization followed by nasal challenges. <br/>Serum levels of IgE, histamine, PAF, IL-1β, and IL-5 were measured <br/>using ELISA, along with PAF and LTB4 levels in the nasal mucosa. <br/>The expression of PDG2 and CCL24 mRNA was analyzed via qRT-<br/>PCR. Histopathological and immunohistochemical evaluations were <br/>performed to assess TGF-β and FOXO1 expression. This thesis <br/>demonstrates that the developed intranasal TE1-ISG provides an <br/>effective delivery platform, showing positive pharmacodynamics <br/>effects in treating OVA-induced rhinitis in rats, and represents a novel <br/>and promising strategy for AR treatment. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | يشهد التهاب الأنف التحسسي ارتفاعًا مستمرًا في معدلات الإصابة، مما يتطلب تطوير استراتيجيات علاجية أكثر فعالية وأمانًا. تهدف هذه الدراسة إلى تصميم نظام توصيل دوائي مبتكر عبر الأنف يعتمد على ليفوسيتريزين (LVC) محمل ضمن جسيمات ترانزإيثوزومية (LVC-TEs) مدمجة في جل حراري متحول(TE1-ISG) ، لتوفير إطلاق مستدام وفعالية علاجية محسّنة.<br/>تم تحضير LVC-TEs باستخدام طريقة الترطيب بالغشاء الرقيق، وتم تحسين الصيغة باستخدام تصميم تجريبي لدراسة تأثير نسب الليسيتين وعوامل التوتر السطحي. أظهرت الصيغة المثلى (TE1)خصائص فيزيائية متميزة، منها حجم جسيمات نانوية 130.64) ± 2.10 نانومتر(، وكفاءة احتواء عالية 92.58) ± (%1.21، وجهد زيتا مناسبmV) 0.52 ± (19.52 ، بالإضافة إلى نمط تحرير دوائي أولي سريع يليه إطلاق مستمر على مدى 24 ساعة.<br/><br/>تم دمج TE1 في جل حراري متحول يحتوي على بولوكزامر 407 و188 و HPMCلتعزيز الالتصاق المخاطي. أظهر الجل خواصًا ملائمة من حيث درجة التحول(33.5°C) ، واللزوجة، وقوة الالتصاق، مع تحسين كبير في النفاذية عبر الغشاء المخاطي الأنفي.<br/><br/>في التقييم الحيوي، تم تحفيز التهاب الأنف التحسسي في نموذج حيواني باستخدام الأوفالبومين (OVA).أظهرت نتائج العلاج بـ TE1-ISG انخفاضًا ملحوظًا في المؤشرات المناعية والالتهابية( مثلIgE ، الهيستامين، PAF، IL-<br/>،CCL24)و ،LTB4 ،PGD2 ،IL-5 ،1β<br/>وتحسنًا في البنية النسيجية للأنف، وانخفاض التعبير عن TGF-β وFOXO1، ما يدل على فعالية علاجية عالية مقارنةً بالليفوسيتريزين النقي.<br/>يثبت هذا العمل أن نظام TE1-ISG يشكل منصة توصيل أنفي فعالة ومبتكرة لعلاج التهاب الأنف التحسسي، مع إمكانية تطبيقه مستقبلًا في الاستخدامات السريرية |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pharmaceutics |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | صيدلانيات |
| 653 #1 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Allergic rhinitis |
| -- | Transethosomes |
| -- | In situ gel |
| -- | ELISA |
| -- | Thin film hydration |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mohamed Ahmed El-Nabarawi |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mahmoud Hassan Teaima |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Samar Fathy Elhabal |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2025 |
| Supervisory body | Mohamed Ahmed El-Nabarawi |
| -- | Mahmoud Hassan Teaima |
| -- | Samar Fathy Elhabal |
| Universities | Cairo University |
| Faculties | Faculty of Pharmacy |
| Department | Department of Pharmaceutics |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 06.04.2026 | 93675 | Cai01.08.08.M.Sc.2025.As.F | 01010110093675000 | 06.04.2026 | 06.04.2026 | Thesis |